Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Optimal timing for cardioversion in patients with atrial fibrillation.

Hellman T, Kiviniemi T, Nuotio I, Biancari F, Vasankari T, Hartikainen J, Lehto M, Airaksinen KE; FinCV Investigators.

Clin Cardiol. 2018 May 26. doi: 10.1002/clc.22986. [Epub ahead of print]

2.

How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ?

Lehtola H, Hartikainen J, Hartikainen P, Kiviniemi T, Nuotio I, Palomäki A, Ylitalo A, Airaksinen KEJ, Mustonen P.

Clin Cardiol. 2018 May;41(5):608-614. doi: 10.1002/clc.22935. Epub 2018 May 10.

3.

Usefulness of the CHA2DS2-VASc and HAS-BLED Scores in Predicting the Risk of Stroke Versus Intracranial Bleeding in Patients With Atrial Fibrillation (from the FibStroke Study).

Jaakkola S, Kiviniemi TO, Nuotio I, Hartikainen J, Mustonen P, Palomäki A, Jaakkola J, Ylitalo A, Hartikainen P, Airaksinen KEJ.

Am J Cardiol. 2018 May 15;121(10):1182-1186. doi: 10.1016/j.amjcard.2018.01.038. Epub 2018 Feb 12.

PMID:
29526276
4.

Clinical manifestations and outcomes of severe warfarin overanticoagulation: from the EWA study.

Jaakkola S, Nuotio I, Kiviniemi TO, Virtanen R, Virta A, Airaksinen KEJ.

Ann Med. 2018 Mar;50(2):164-171. doi: 10.1080/07853890.2017.1407494. Epub 2017 Nov 23.

PMID:
29156997
5.

Intensity of anticoagulation and risk of thromboembolism after elective cardioversion of atrial fibrillation.

Hellman T, Kiviniemi T, Nuotio I, Vasankari T, Hartikainen J, Lip GYH, Airaksinen KEJ.

Thromb Res. 2017 Aug;156:163-167. doi: 10.1016/j.thromres.2017.06.026. Epub 2017 Jun 22.

PMID:
28662483
6.

Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation-The EWA study.

Jaakkola S, Nuotio I, Kiviniemi TO, Virtanen R, Issakoff M, Airaksinen KEJ.

PLoS One. 2017 Apr 20;12(4):e0175975. doi: 10.1371/journal.pone.0175975. eCollection 2017.

7.

Stroke recurrence in patients with atrial fibrillation: concomitant carotid artery stenosis doubles the risk.

Lehtola H, Airaksinen KEJ, Hartikainen P, Hartikainen JEK, Palomäki A, Nuotio I, Ylitalo A, Kiviniemi T, Mustonen P.

Eur J Neurol. 2017 May;24(5):719-725. doi: 10.1111/ene.13280. Epub 2017 Mar 20.

PMID:
28317289
8.

Prediction of ineffective elective cardioversion of atrial fibrillation: a retrospective multi-center patient cohort study.

Hellman T, Kiviniemi T, Vasankari T, Nuotio I, Biancari F, Bah A, Hartikainen J, Mäkäräinen M, Airaksinen KE.

BMC Cardiovasc Disord. 2017 Jan 18;17(1):33. doi: 10.1186/s12872-017-0470-0.

9.

Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study.

Bah A, Nuotio I, Grönberg T, Ylitalo A, Airaksinen KE, Hartikainen JE.

Ann Med. 2017 May;49(3):254-259. doi: 10.1080/07853890.2016.1267869. Epub 2016 Dec 31.

PMID:
28042730
10.

Predicting Unsuccessful Electrical Cardioversion for Acute Atrial Fibrillation (from the AF-CVS Score).

Jaakkola S, Lip GY, Biancari F, Nuotio I, Hartikainen JE, Ylitalo A, Airaksinen KE.

Am J Cardiol. 2017 Mar 1;119(5):749-752. doi: 10.1016/j.amjcard.2016.11.026. Epub 2016 Dec 2.

PMID:
28017305
11.

Stroke as the First Manifestation of Atrial Fibrillation.

Jaakkola J, Mustonen P, Kiviniemi T, Hartikainen JE, Palomäki A, Hartikainen P, Nuotio I, Ylitalo A, Airaksinen KE.

PLoS One. 2016 Dec 9;11(12):e0168010. doi: 10.1371/journal.pone.0168010. eCollection 2016.

12.

Mortality after stroke in patients with paroxysmal and chronic atrial fibrillation - The FibStroke study.

Palomäki A, Kiviniemi T, Mustonen P, Odei C, Hartikainen JEK, Nuotio I, Ylitalo A, Hartikainen P, Biancari F, Airaksinen KEJ.

Int J Cardiol. 2017 Jan 15;227:869-874. doi: 10.1016/j.ijcard.2016.06.107. Epub 2016 Jun 23.

PMID:
27639597
13.

Postoperative Strokes and Intracranial Bleeds in Patients With Atrial Fibrillation: The FibStroke Study.

Palomäki A, Kiviniemi T, Hartikainen JE, Mustonen P, Ylitalo A, Nuotio I, Hartikainen P, Jaakkola J, Luite R, Airaksinen KE.

Clin Cardiol. 2016 Aug;39(8):471-6. doi: 10.1002/clc.22554. Epub 2016 May 30.

14.

Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study).

Grönberg T, Hartikainen JE, Nuotio I, Biancari F, Ylitalo A, Airaksinen KE.

Am J Cardiol. 2016 Apr 15;117(8):1294-8. doi: 10.1016/j.amjcard.2016.01.024. Epub 2016 Jan 29.

PMID:
26892448
15.

Strokes after cardioversion of atrial fibrillation--The FibStroke study.

Palomäki A, Mustonen P, Hartikainen JE, Nuotio I, Kiviniemi T, Ylitalo A, Hartikainen P, Lehtola H, Luite R, Airaksinen KE.

Int J Cardiol. 2016 Jan 15;203:269-73. doi: 10.1016/j.ijcard.2015.10.168. Epub 2015 Oct 20.

PMID:
26519683
16.

Underuse of anticoagulation in stroke patients with atrial fibrillation--the FibStroke Study.

Palomäki A, Mustonen P, Hartikainen JE, Nuotio I, Kiviniemi T, Ylitalo A, Hartikainen P, Airaksinen KE.

Eur J Neurol. 2016 Jan;23(1):133-9. doi: 10.1111/ene.12820. Epub 2015 Aug 11.

PMID:
26263442
17.

Ventricular rate during acute atrial fibrillation and outcome of electrical cardioversion: The FinCV Study.

Jaakkola J, Hartikainen JE, Kiviniemi T, Nuotio I, Nammas W, Grönberg T, Karmi A, Ylitalo A, Airaksinen KE.

Ann Med. 2015 Jun;47(4):341-5. doi: 10.3109/07853890.2015.1031821. Epub 2015 May 6.

PMID:
25943162
18.

Can we predict the failure of electrical cardioversion of acute atrial fibrillation? The FinCV study.

Grönberg T, Hartikainen JE, Nuotio I, Biancari F, Vasankari T, Nikkinen M, Ylitalo A, Airaksinen KE.

Pacing Clin Electrophysiol. 2015 Mar;38(3):368-75. doi: 10.1111/pace.12561. Epub 2014 Dec 23.

PMID:
25534241
19.

Time to cardioversion for acute atrial fibrillation and thromboembolic complications.

Nuotio I, Hartikainen JE, Grönberg T, Biancari F, Airaksinen KE.

JAMA. 2014 Aug 13;312(6):647-9. doi: 10.1001/jama.2014.3824. No abstract available.

PMID:
25117135
20.

Cardioversion in Acute Atrial Fibrillation Without Anticoagulation.

Airaksinen KJ, Nammas W, Nuotio I.

J Atr Fibrillation. 2013 Dec 31;6(4):970. doi: 10.4022/jafib.970. eCollection 2013 Dec. Review.

21.

Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study.

Airaksinen KE, Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, Hartikainen JE.

J Am Coll Cardiol. 2013 Sep 24;62(13):1187-92. doi: 10.1016/j.jacc.2013.04.089. Epub 2013 Jul 10.

22.

Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study.

Grönberg T, Nuotio I, Nikkinen M, Ylitalo A, Vasankari T, Hartikainen JE, Airaksinen KE.

Europace. 2013 Oct;15(10):1432-5. doi: 10.1093/europace/eut106. Epub 2013 May 17.

PMID:
23687124
23.

Expression of common familial dyslipidemias in early childhood.

Lapinleimu J, Lapinleimu H, Nuotio IO, Rönnemaa T, Simell OG, Viikari JS; STRIP study group.

Atherosclerosis. 2009 Jun;204(2):573-9. doi: 10.1016/j.atherosclerosis.2008.10.004. Epub 2008 Oct 14.

PMID:
19026413
24.

Effect of 12-month statin therapy on antioxidant potential of LDL and serum antioxidant vitamin concentrations.

Vasankari T, Ahotupa M, Viikari J, Nuotio I, Strandberg T, Vanhanen H, Gylling H, Miettinen T, Tikkanen MJ.

Ann Med. 2004;36(8):618-22.

PMID:
15768833
25.

Effects of statin therapy on circulating conjugated dienes, a measure of LDL oxidation.

Vasankari T, Ahotupa M, Viikari J, Nuotio I, Vuorenmaa T, Strandberg T, Vanhanen H, Tikkanen MJ.

Atherosclerosis. 2005 Mar;179(1):207-9. Epub 2005 Jan 23. No abstract available.

PMID:
15721029
26.

Comparison of GenFlex Tag array and Pyrosequencing in SNP genotyping.

Chen DC, Saarela J, Nuotio I, Jokiaho A, Peltonen L, Palotie A.

J Mol Diagn. 2003 Nov;5(4):243-9.

27.

Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q.

Pajukanta P, Allayee H, Krass KL, Kuraishy A, Soro A, Lilja HE, Mar R, Taskinen MR, Nuotio I, Laakso M, Rotter JI, de Bruin TW, Cantor RM, Lusis AJ, Peltonen L.

Am J Hum Genet. 2003 Apr;72(4):903-17. Epub 2003 Mar 12.

28.

Vitamin D and attainment of peak bone mass among peripubertal Finnish girls: a 3-y prospective study.

Lehtonen-Veromaa MK, Möttönen TT, Nuotio IO, Irjala KM, Leino AE, Viikari JS.

Am J Clin Nutr. 2002 Dec;76(6):1446-53.

PMID:
12450915
29.

Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia.

Vakkilainen J, Pajukanta P, Cantor RM, Nuotio IO, Lahdenperä S, Ylitalo K, Pihlajamäki J, Kovanen PT, Laakso M, Viikari JS, Peltonen L, Taskinen MR.

Eur J Hum Genet. 2002 Sep;10(9):547-52.

30.

A candidate gene study in low HDL-cholesterol families provides evidence for the involvement of the APOA2 gene and the APOA1C3A4 gene cluster.

Lilja HE, Soro A, Ylitalo K, Nuotio I, Viikari JS, Salomaa V, Vartiainen E, Taskinen MR, Peltonen L, Pajukanta P.

Atherosclerosis. 2002 Sep;164(1):103-11.

PMID:
12119199
31.

Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes.

Liu ML, Ylitalo K, Vakkilainen J, Nuotio I, Valkonen M, Lahdenperä S, Viikari J, Taskinen MR.

Ann Med. 2002;34(1):48-54.

PMID:
12014434
32.
34.
35.

Carotid artery intima-media thickness in Finnish families with familial combined hyperlipidemia.

Ylitalo K, Syvänne M, Salonen R, Nuotio I, Taskinen MR, Salonen JT.

Atherosclerosis. 2002 May;162(1):171-8.

PMID:
11947911
36.

LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins.

Vakkilainen J, Jauhiainen M, Ylitalo K, Nuotio IO, Viikari JS, Ehnholm C, Taskinen MR.

J Lipid Res. 2002 Apr;43(4):598-603.

37.

Recognition of familial dyslipidemias in 5-year-old children using the lipid phenotypes of parents. The STRIP project.

Lapinleimu J, Nuotio IO, Lapinleimu H, Simell OG, Rask-Nissila L, Viikari JS.

Atherosclerosis. 2002 Feb;160(2):417-23.

PMID:
11849666
38.

Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia.

Ylitalo K, Pajukanta P, Meri S, Cantor RM, Mero-Matikainen N, Vakkilainen J, Nuotio I, Taskinen MR.

Arterioscler Thromb Vasc Biol. 2001 May;21(5):838-43.

PMID:
11348883
39.

Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL families.

Ylitalo K, Large V, Pajukanta P, Reynisdottir S, Porkka KV, Vakkilainen J, Nuotio I, Taskinen MR, Arner P.

Atherosclerosis. 2000 Dec;153(2):373-81.

PMID:
11164426
40.

Two loci on chromosomes 2 and X for premature coronary heart disease identified in early- and late-settlement populations of Finland.

Pajukanta P, Cargill M, Viitanen L, Nuotio I, Kareinen A, Perola M, Terwilliger JD, Kempas E, Daly M, Lilja H, Rioux JD, Brettin T, Viikari JS, Rönnemaa T, Laakso M, Lander ES, Peltonen L.

Am J Hum Genet. 2000 Dec;67(6):1481-93. Epub 2000 Nov 13.

41.

A 1-year prospective study on the relationship between physical activity, markers of bone metabolism, and bone acquisition in peripubertal girls.

Lehtonen-Veromaa M, Möttönen T, Irjala K, Nuotio I, Leino A, Viikari J.

J Clin Endocrinol Metab. 2000 Oct;85(10):3726-32.

PMID:
11061531
42.

Influence of physical activity on ultrasound and dual-energy X-ray absorptiometry bone measurements in peripubertal girls: a cross-sectional study.

Lehtonen-Veromaa M, Möttönen T, Nuotio I, Heinonen OJ, Viikari J.

Calcif Tissue Int. 2000 Apr;66(4):248-54.

PMID:
10742439
43.

Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels.

Pajukanta P, Terwilliger JD, Perola M, Hiekkalinna T, Nuotio I, Ellonen P, Parkkonen M, Hartiala J, Ylitalo K, Pihlajamäki J, Porkka K, Laakso M, Viikari J, Ehnholm C, Taskinen MR, Peltonen L.

Am J Hum Genet. 1999 May;64(5):1453-63.

44.

Coronary flow reserve in young men with familial combined hyperlipidemia.

Pitkänen OP, Nuutila P, Raitakari OT, Porkka K, Iida H, Nuotio I, Rönnemaa T, Viikari J, Taskinen MR, Ehnholm C, Knuuti J.

Circulation. 1999 Apr 6;99(13):1678-84.

PMID:
10190876
45.

Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia.

Tahvanainen E, Pajukanta P, Porkka K, Nieminen S, Ikävalko L, Nuotio I, Taskinen MR, Peltonen L, Ehnholm C.

Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1810-7.

PMID:
9812922
46.

Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23.

Pajukanta P, Nuotio I, Terwilliger JD, Porkka KV, Ylitalo K, Pihlajamäki J, Suomalainen AJ, Syvänen AC, Lehtimäki T, Viikari JS, Laakso M, Taskinen MR, Ehnholm C, Peltonen L.

Nat Genet. 1998 Apr;18(4):369-73.

PMID:
9537421
47.

Glucose intolerance in familial combined hyperlipidaemia. EUFAM study group.

Vakkilainen J, Porkka KV, Nuotio I, Pajukanta P, Suurinkeroinen L, Ylitalo K, Viikari JS, Ehnholm C, Taskinen MR.

Eur J Clin Invest. 1998 Jan;28(1):24-32.

PMID:
9502184
48.

Phenotype expression in familial combined hyperlipidemia.

Porkka KV, Nuotio I, Pajukanta P, Ehnholm C, Suurinkeroinen L, Syvänne M, Lehtimäki T, Lahdenkari AT, Lahdenperä S, Ylitalo K, Antikainen M, Perola M, Raitakari OT, Kovanen P, Viikari JS, Peltonen L, Taskinen MR.

Atherosclerosis. 1997 Sep;133(2):245-53.

PMID:
9298685
49.

No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families.

Pajukanta P, Porkka KV, Antikainen M, Taskinen MR, Perola M, Murtomäki-Repo S, Ehnholm S, Nuotio I, Suurinkeroinen L, Lahdenkari AT, Syvänen AC, Viikari JS, Ehnholm C, Peltonen L.

Arterioscler Thromb Vasc Biol. 1997 May;17(5):841-50.

PMID:
9157946
50.

Associations between diet and the hyperapobetalipoproteinemia phenotype expression in children and young adults: the Cardiovascular Risk in Young Finns Study.

Nuotio IO, Raitakari OT, Porkka KV, Räsänen L, Moilanen T, Viikari JS.

Arterioscler Thromb Vasc Biol. 1997 May;17(5):820-5.

PMID:
9157943

Supplemental Content

Loading ...
Support Center